{
    "nct_id": "NCT04468607",
    "official_title": "A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer",
    "inclusion_criteria": "* ECOG performance status of 0 or 1\n* Life expectancy of at least 12 weeks\n* Histologically or cytologically documented invasive CRC: incurable, unresectable, locally advanced or metastatic CRC previously treated with multimodality therapy or mCRC\n* Locally advanced or metastatic CRC that has relapsed or is refractory to established therapies\n* Prior disease progression (or intolerance) following oxaliplatin, irinotecan, fluoropyrimidines, and anti-EGFR monoclonal antibodies\n* An archival tissue specimen or fresh baseline biopsy (when archival is not available) is required for enrollment into the study\n* Measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Non-measurable evaluable disease is acceptable for dose-escalation.\n* Adequate hematologic and end organ function\n* Acute, clinically significant treatment-related toxicity from prior therapy resolved to Grade â‰¤ 1 prior to study entry\n\nExpansion Cohort-Specific Inclusion Criteria\n\n* MSS or MSI-L disease as determined by polymerase chain reaction (PCR) and/or IHC\n* Measurable disease by RECIST v1.1 with at least one measurable target lesion in the expansion cohort\n* Progression must have occurred during or after most recent treatment for locally advanced or metastatic colorectal cancer\n* For patients enrolled in either a dedicated biopsy cohort or other expansion cohorts where biopsy is clinically feasible, willingness to consent to mandatory fresh pretreatment and on-treatment biopsies of safely accessible tumor lesions\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or breastfeeding, or intending to become pregnant during the study or within 4 months after the final dose of BLYG8824A\n* Significant cardiopulmonary dysfunction\n* Known clinically significant liver disease\n* Positive serologic or PCR test results for acute or chronic HBV infection\n* Acute or chronic HCV infection\n* HIV seropositivity\n* Poorly controlled Type 2 diabetes mellitus\n* Current treatment with medications that are well known to prolong the QT interval\n* Primary CNS malignancy, untreated CNS metastases, or active CNS metastases\n* Leptomeningeal disease\n* Spinal cord compression that has not been definitively treated with surgery and/or radiation\n* History of autoimmune disease\n* Prior allogeneic stem cell or solid organ transplantation",
    "miscellaneous_criteria": ""
}